Pharmacists’ Knowledge Gap about Oncology Genetic Testing, Benefit Design

May/June 2012, Vol 5, No 3 - Conference Highlights AMCP

Knowledge of pharmacogenomics—a collection of genomic factors contributing to individual variability in response to drug therapy—enhances the ability to diagnose, prevent, and treat disease. Although understanding the correct application of pharmacogenomics may be essential to providing cost-effective care, barriers include the absence of provider knowledge and inappropriate reimbursement strategies. Angela Luong, PharmD, and colleagues at OPTUMInsight conducted a survey of pharmacists regarding their knowledge of genetic testing and utilization strategies.

A total of 19 pharmacists at 4 different managed care organizations responded to the survey, revealing a basic lack of knowledge of pharmacogenomics (or personalized medicine). The majority of respondents (84%) agreed or strongly agreed that pharmacogenomics will have an impact on healthcare expenditures and that pharmacists should have a good knowledge base of pharmacogenomics-related drug therapies and tests; however, the majority (84%) did not routinely have much education in this area. Overall, 95% of participants scored <60% on a pharmacogenomics knowledge test.

In addition, knowledge of pharmacogenomics does not necessarily have a direct impact on patient care or benefit design. Only 47% (n = 9) of respondents said their plan requires prior authorization (PA) for the use of the US Food and Drug Administration–approved companion diagnostic test for vemurafenib compared with 58% (n = 11) of respondents whose plans require a PA for the companion test for crizotinib. By contrast, only 16% (n = 3) of respondents said their plans require testing for HER2 mutation before prescribing trastuzumab compared with 58% (n = 11) of respondents whose plans do not require testing and 26% (n = 5) who did not know whether their plans require such testing.

Furthermore, the majority of respondents did not know whether their plans had reimbursement policies related to pharmacogenomics. Overall, this survey reveals gaps in pharmacists’ knowledge of pharmacogenomics utility and its related benefit design strategies. As a result of the growing impact of personalized medicine and tests for pharmacogenomics, understanding and designing appropriate benefit policies are essential; the group at OPTUMInsight plans on continuing this research with a larger pharmacist population. [Luong A, Lal L, King K, et al. Assessment for clinical utility of currently available oncology genetic tests and assessment of pharmacogenomics knowledge of pharmacists.]

Related Items
Can Technologic Innovations and Formulary Considerations Improve Healthcare Outcomes?
Charles Bankhead
June 2018 Vol 11, No 4 published on June 25, 2018 in Conference Highlights AMCP
AMCP Nexus 2017 Highlights
December 2017 Vol 10, No 9 published on January 3, 2018 in Conference Highlights AMCP
Challenges and Opportunities in Managing Type 2 Diabetes
Laura Morgan
June 2017 Vol 10, No 4 published on June 22, 2017 in Conference Highlights AMCP
Payers’ Perspective: Incorporating Real-World Evidence in Patient Care
Lilly Ostrovsky
April 2017 Vol 10, No 2 published on April 18, 2017 in Conference Correspondent, Conference Highlights AMCP
Implications of Real-World Data and Pharmacoeconomics for Managed Care
Lilly Ostrovsky
May 2016 Vol 9, No 3 published on May 25, 2016 in Conference Highlights AMCP
Last modified: July 13, 2012
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME